Document Type
Article
Publication Date
12-2015
Keywords
treatment-naive patients; fixed-dose combination; hiv-1 infection; tenofovir df;efavirenz; safety; lamivudine; efficacy; therapy; nevirapine
Abstract
Millions of people cannot access essential medicines they need for deadly diseases like malaria, tuberculosis (TB) and HIV/AIDS. There is good information on the need for drugs for these diseases but until now, no global estimate of the impact drugs are having on this burden. This paper presents a model measuring companies' key malaria, TB and HIV/AIDS drugs' consequences for global health (global-health-impact.org). It aggregates drugs' impacts in several ways-by disease, country and originator-company. The methodology can be extended across diseases as well as drugs to provide a more extensive picture of the impact companies' drugs are having on the global burden of disease. The study suggests that key malaria, TB and HIV/AIDS drugs are, together, ameliorating about 37% of the global burden of these diseases and Sanofi, Novartis, and Pfizer's drugs are having the largest effect on this burden. Moreover, drug impacts vary widely across countries. This index provides important information for policy makers, pharmaceutical companies, countries, and other stake-holders that can help increase access to essential medicines.
Publisher Attribution
Hassoun, N. (2015). The Global Health Impact Index: Promoting Global Health. PloS one, 10(12), e0141374.
Recommended Citation
Hassoun, Nicole, "The Global Health Impact Index: Promoting Global Health" (2015). Philosophy Faculty Scholarship. 2.
https://orb.binghamton.edu/philosophy_fac/2